While excellent inhibitors were developed over the years to block the anti-apoptotic defense mechanisms in cancer cells (e.g., BCL-2 and Bcl-xL inhibitors), lack of specific predictive biomarkers for their use has limited their utility. This evidence concerns the gene BCL2 and cancer.